Top 5 Best-Selling Cancer Drugs

4. Imbruvica  

Total Sales: 15.2 billion 

Imbruvica (ibrutinib), a BTK inhibitor, is a top best-selling cancer drug for chronic lymphocytic leukemia, small lymphocytic lymphoma, and Waldenstrom’s macroglobulinemia. Approved by the FDA in 2013, it blocks Bruton’s tyrosine kinase, inhibiting cancer cell growth. Imbruvica is a commercial success, generating around $7.2 billion in global sales in 2022, reflecting its effectiveness and widespread clinical use.